SCHEMBL1681044

SCHEMBL1681044

N#CNC(=NCc1ccc(OCc2ccccc2)cc1)c1ccc2ncccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.46
NAMPT P43490 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
MET P08581 1/20 0.41
P2RX7 Q99572 1/20 0.39
BCAT1 P54687 1/20 0.39
ALOX15 P16050 1/20 0.38
HTT P42858 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
GUSB P08236 1/20 0.38
RAPGEF3 O95398 1/20 0.38
MAOB P27338 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
ALDH1A1 P00352 2/20 0.37
NR4A1 P22736 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1681032 0.86 CYP3A4 (0.47) CYP3A4SMN1; SMN2METBCAT1ALOX15
SCHEMBL12352660 0.82 CYP3A4 (0.46) CYP3A4NAMPTSMN1; SMN2METBCAT1
SCHEMBL1681042 0.82 CYP3A4 (0.46) CYP3A4NAMPTSMN1; SMN2METBCAT1
SCHEMBL1681043 0.82 CYP3A4 (0.46) CYP3A4NAMPTSMN1; SMN2METBCAT1
SCHEMBL1681028 0.76 CYP3A4 (0.46) CYP3A4SMN1; SMN2METBCAT1ALOX15
SCHEMBL12352658 0.76 CYP3A4 (0.46) CYP3A4SMN1; SMN2METBCAT1ALOX15
SCHEMBL1681030 0.76 CYP3A4 (0.46) CYP3A4SMN1; SMN2METBCAT1ALOX15
SCHEMBL1681256 0.75 CYP3A4 (0.73) CYP3A4SMN1; SMN2METMAOBGAA
SCHEMBL1680422 0.74 HDAC1 (0.60) CYP3A4SMN1; SMN2BCAT1HTTMEN1
SCHEMBL9216865 0.74 GRK2 (0.47) NAMPTSMN1; SMN2HTTGUSBMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 CYP3A4 61/4885NAMPT 1609/4885SMN1; SMN2 4831/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD CYP3A4 1535/4885NAMPT 1233/4885SMN1; SMN2 4683/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 CYP3A4 104/4885NAMPT 1668/4885SMN1; SMN2 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.